Eurosurv. Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living syste

[tetano]

• Thomas Harder[SUP]1[/SUP] , Wiebe Külper-Schiek[SUP]1[/SUP] , Sarah Reda[SUP]1[/SUP] , Marina Treskova-Schwarzbach[SUP]1[/SUP] , Judith Koch[SUP]1[/SUP] , Sabine Vygen-Bonnet[SUP]1[/SUP] , Ole Wichmann[SUP]1[/SUP]

The Delta variant has become the dominant strain of SARS-CoV-2. We summarised the evidence on COVID-19 vaccine effectiveness (VE) identified in 17 studies that investigated VE against different endpoints. Pooled VE was 63.1% (95% confidence interval (CI): 40.9–76.9) against asymptomatic infection, 75.7% (95% CI: 69.3–80.8) against symptomatic infection and 90.9% (95% CI: 84.5–94.7) against hospitalisation. Compared with the Alpha variant, VE against mild outcomes was reduced by 10–20%, but fully maintained against severe COVID-19.

full article



https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.41.2100920#abstract_content